Item 1B. Unresolved Staff Comments
Item
1B. Unresolved Staff Comments
None.
Item
1C. Cybersecurity
We
operate in the biotechnology sector, which is subject to various cybersecurity risks that could adversely affect our business, financial
condition, and results of operations, including intellectual property theft; fraud; extortion; harm to employees or customers; violation
of privacy laws and other litigation and legal risk; and reputational risk. We have implemented a risk-based approach to identify and
assess the cybersecurity threats that could affect our business and information systems. We require third-party service providers with
access to personal, confidential or proprietary information to implement and maintain comprehensive cybersecurity practices consistent
with applicable legal standards and industry best practices.
The
Company is currently in the process of implementing a more formalized cybersecurity program.
In
light of the pervasive and increasing threat from cyberattacks, the Board and the Audit Committee, with input from management, assess
the Company’s cybersecurity threats and the measures implemented by the Company to mitigate and prevent cyberattacks. The Audit
Committee consults with management regarding ongoing cybersecurity initiatives, and requests management to report to the Audit Committee
or the full Board regularly on their assessment of the Company’s cybersecurity program and risks.
As
of the date of this Annual Report, the Company is not aware of any risks from cybersecurity threats that have materially affected or
are reasonably likely to materially affect the Company, including its business strategy, results of operations, or financial condition.
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.